BAXDELA (delafloxacin) | Your Path Forward
BAXDELA ® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.
BAXDELA ® safely and effectively. See full prescribing information for BAXDELA. BAXDELA (delafloxacin) tablets, for oral use BAXDELA (delafloxacin) for injection, for intravenous use Initial U.S. Approval: 2017 . WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS
BAXDELA (delafloxacin) | Efficacy
BAXDELA ® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.
BAXDELA (delafloxacin) ABSSSI | About Baxdela
BAXDELA ® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.
• Take BAXDELA tablets 2 times a day exactly as your healthcare provider tells you to take it. • If you have kidney problems, talk with your doctor about how you should take BAXDELA. • BAXDELA can be taken with or without food.
BAXDELA (delafloxacin) | Dosing and Administration
Simplify ABSSSI treatment with BAXDELA (delafloxacin) through flexible IV and oral dosing. See BOXED WARNING.
BAXDELA (delafloxacin) | Safety | Tolerability
BAXDELA ® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.
BAXDELA (delafloxacin) | Mechanism of Action
BAXDELA ® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.
ABSSSI Safety & Tolerability - BAXDELA
BAXDELA ® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.
BAXDELA (delafloxacin) | Microbiological Activity in ABSSSI
BAXDELA ® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.